Maropitant Production Cost Reports

The report provides a detailed analysis essential for establishing a maropitant production plant. It encompasses all critical aspects necessary for maropitant production, including the cost of maropitant production, maropitant plant cost, maropitant production costs, and the overall maropitant production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a maropitant production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Maropitant, mainly used as maropitant citrate, is a neurokinin-1 (NK1) receptor antagonist. It is mainly utilised in the veterinary pharmaceutical industry to prevent and treat vomiting and motion sickness in dogs and cats, developed by Zoetis and marketed as Cerenia in injectable solutions and oral tablets.

It targets central and peripheral emetic receptors by blocking substance P in the central nervous system, which makes it a highly specialised treatment approved for dogs since 2007 and cats since 2012. It effectively controls vomiting from chemotherapy, general gastrointestinal disorders with supportive care, motion sickness during travel (via tablets), and perioperative nausea associated with anaesthesia and surgery.

Maropitant's market growth is propelled by surging global pet ownership, heightened pet humanisation leading to increased veterinary healthcare spending, and expanded clinical adoption. Its function as a premier antiemetic for dogs and cats managing vomiting from motion sickness, chemotherapy, anaesthesia, and gastroenteritis contributes to its market demand. Additionally, formulation innovations like palatable fast-dissolving tablets, long-acting injectables (e.g., Dechra's Emeprev launching early 2026), and improved compliance for diverse pet sizes boost the market growth.

Moreover, mature demand in North America, Europe, and Japan from veterinarian reliance and brand loyalty, along with rapid expansion in Asia-Pacific and Latin America via infrastructure growth and licensing deals, fuels market expansion. However, regulatory approvals and generic competition post-patent expiry impacts industrial maropitant procurement, with generic entrants (e.g., Elmaro, Emevet) offering price advantages but requiring dossier reviews, DMF filings, and equivalence testing for injectables or tablets.

Raw Material for Maropitant Production

According to the maropitant production plant project report, the raw material for maropitant production includes 2-methoxy-5-tert-butyl-benzylamine.

Production Process of Maropitant

The extensive maropitant production cost report consists of the following major industrial production process:

1. Production via a multi-step organic process: The production process of maropitant involves building its quinuclidine core. It starts with reductive amination of a substituted benzylamine, like 2-methoxy-5-tert-butyl-benzylamine, and a ketone to form the key amine linkage, followed by benzhydrylation to attach the critical diphenylmethyl group at the C2 position. The process utilises activated mesylate or triflate intermediates under basic conditions in solvents such as DCM or 2-MeTHF. The process incorporates Michael additions, pressure hydrogenation, hydroxyl protection/deprotection, nucleophilic substitutions at reflux (e.g., 100 degree Celsius in DMF), and chromatography purification to produce maropitant.

Properties of Maropitant

Maropitant, a neurokinin-1 (NK1) receptor antagonist mainly used as its citrate salt in veterinary medicine, consists of a free base form (C32H40N2O) with a molecular weight of 468.7 g/mol. It has poor water solubility (<0.1 mg/mL), good DMSO solubility (33.33 mg/mL), high plasma protein binding (99.5%), low volume of distribution (9 L/kg), and bioavailability of 91% subcutaneously but 24% orally. The citrate monohydrate (C38H50N2O9), molecular weight 678.8 g/mol, offers improved solubility for injectables (10 mg/mL solutions) and tablets via excipients like sulfobutylether-β-cyclodextrin, with a topological polar surface area of 158 Ų, 6 H-bond donors, 11 acceptors, and 13 rotatable bonds, appearing as stable peach-coloured solids or clear liquids under GMP conditions.